Quarterly report · Q1
8129.TEDINET S100RNXE
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥351.2bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥1.39T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥324.3bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥1.9bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥2.3bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥2.5bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥19.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.5bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.0bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥734.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥715.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥710.1bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥493.4bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥472.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥241.1bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥242.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥243.7bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥92.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥86.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥23.07 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥196.7 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.22 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥21.12 | 2023-04-01 → 2023-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥180.67 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.86 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 32.8% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥14.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥14.9bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥810m |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥22.8bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥22.8bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥1m |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥112m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥2.7bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥608m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥2.0bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥293m |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥339.1bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥326.6bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥12.5bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥2.2bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥1.5bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥1.1bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥338m |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥35m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥366.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥351.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥14.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥2.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥14.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥14.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥401m |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥22.2bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥22.2bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥133m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.5bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥612m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥288m |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥312.7bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥300.3bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥12.4bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.2bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥356m |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥94m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥338.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥324.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥14.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥2.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 417
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes financial instruments quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes securities quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes derivatives quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |